SCHEMBL7658287

SCHEMBL7658287

COc1ccc2c(c1)Oc1sc(C)cc1C(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
MAPT P10636 4/20 0.40
TDP1 Q9NUW8 2/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
LRRK2 Q5S007 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RET P07949 1/20 0.39
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MDM2 Q00987 2/20 0.37
CHEK1 O14757 1/20 0.37
SNCA P37840 1/20 0.37
TLK2 Q86UE8 2/20 0.37
PDPK1 O15530 1/20 0.37
LMNA P02545 1/20 0.37
CDK1 P06493 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7658309 0.84 ALDH1A1 (0.46) ALDH1A1MAPTTDP1TP53POLB
SCHEMBL7661672 0.82 CES1 (0.42) ALDH1A1MAPTTP53LRRK2RET
SCHEMBL7666555 0.82 KMT2A (0.37) ALDH1A1MAPTLRRK2SMN1; SMN2LMNA
SCHEMBL7658523 0.80 MAPT (0.47) ALDH1A1MAPTTDP1TP53POLB
SCHEMBL7665527 0.78 MAPT (0.54) ALDH1A1MAPTTDP1POLBL3MBTL1
Dimethylamine SCHEMBL7666545 0.76 MAPT (0.44) ALDH1A1MAPTTDP1TP53POLB
SCHEMBL11506987 0.76 ALDH1A1 (0.49) ALDH1A1MAPTTDP1TP53POLB
SCHEMBL7659353 0.76 MMP12 (0.47) ALDH1A1MAPTTDP1TP53POLB
SCHEMBL7660369 0.74 TGM2 (0.37) LRRK2
SCHEMBL7664938 0.74 CES1 (0.42) MAPTTP53POLBLRRK2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP claimed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT ALDH1A1 366/4885MAPT 15/4885TDP1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.